Full-Time
Posted on 4/9/2025
Biotechnology for autoimmune disease treatments
No salary listed
Senior, Expert
Boston, MA, USA + 1 more
More locations: Remote in USA
argenx develops immunology solutions aimed at treating severe autoimmune diseases and cancer. The company focuses on creating therapeutic antibodies, with a notable product being cusatuzumab, which is in development with Janssen R&D to address hematological malignancies like leukemia. argenx collaborates with academic institutions and industry partners to turn scientific research into viable treatments. Its business model emphasizes research and development, followed by licensing agreements and partnerships for bringing products to market. Revenue is generated through milestone payments, royalties, and sales of its products.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Ghent, Belgium
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trialEuropean Commission (EC) decision on marketing authorization application (MAA) expected within approximately two monthsAmsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.“Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.”VYVGART for subcutaneous injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. Treatment is initiated with a weekly dose regimen and may be adjusted to every other week based on clinical evaluation.The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. In the ADHERE study, 66.5% (214/322) of patients treated with VYVGART, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo
argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.
Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML
Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.
$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024